CD274 and nonpapillary renal cell carcinoma: The HCRN GU16-260-Cohort, a Phase II Study, demonstrated efficacy of Nivolumab monotherapy in treatment-naive ccRCC patients, particularly showing significant effects in patients with PD-L1 expression above 20%, while patients with 0% PD-L1 expression showed poorer responses.